AUT 00063
Alternative Names: AUT-00063Latest Information Update: 28 Aug 2019
At a glance
- Originator Autifony Therapeutics
- Class Small molecules
- Mechanism of Action Shaw potassium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Hearing loss; Tinnitus
Highest Development Phases
- No development reported Hearing loss; Tinnitus
Most Recent Events
- 28 Aug 2019 No development reported - Phase-II for Hearing loss in USA, United Kingdom (PO)
- 28 Aug 2019 No development reported - Phase-II for Tinnitus in United Kingdom (PO)
- 01 Apr 2017 Autifony Therapeutics completes a phase II trial in Hearing loss in United Kingdom (PO) (NCT02832128)